This pragmatic analysis investigated how the face of radiation oncology randomized trials differs from that of systemic therapy trials and the implications of such on the global stage. First of all, despite roughly half of patients with cancer receiving radiation, less than one in ten of all randomized trials performed from 2014-2017 evaluated radiation, with half of those looking at combining radiation with systemic therapy and/or changing fractionation. This could be due to only 17% of radiation trials receiving industry funding compared to 79% of systemic therapy trials. What’s more, over three-quarters are conducted exclusively in high-income countries. | Dodkins, Int J Radiat Oncol Biol Phys 2022


Popular Posts